Development of Dual PLD1/2 and PLD2 Selective Inhibitors from a Common 1,3,8-Triazaspiro[4.5]decane Core: Discovery of ML298 and ML299 That Decrease Invasive Migration in U87-MG Glioblastoma Cells
Journal of Medicinal Chemistry2013Vol. 56(6), pp. 2695–2699
Citations Over TimeTop 10% of 2013 papers
Matthew C. O’Reilly, Sarah Scott, Kyle A. Brown, Thomas H. Oguin, Paul G. Thomas, J. Scott Daniels, Ryan D. Morrison, H. Alex Brown, Craig W. Lindsley
Abstract
An iterative parallel synthesis effort identified a PLD2 selective inhibitor, ML298 (PLD1 IC50 > 20000 nM, PLD2 IC50 = 355 nM) and a dual PLD1/2 inhibitor, ML299 (PLD1 IC50 = 6 nM, PLD2 IC50 = 20 nM). SAR studies revealed that a small structural change (incorporation of a methyl group) increased PLD1 activity within this classically PLD2-preferring core and that the effect was enantiospecific. Both probes decreased invasive migration in U87-MG glioblastoma cells.
Related Papers
- → Accumulating insights into the role of phospholipase D2 in human diseases(2015)28 cited
- → Phospholipase D as a Therapeutic Target in Brain Disorders(2011)24 cited
- → Expression of phospholipase D isoforms in mammalian cells(1999)83 cited
- → Phospholipase D(2000)82 cited
- → Phopholipase D Isoform 1 is Critical for α 1 ‐Adrenergic Receptor Stimulation of Cell Growth and Motility Events(2006)